Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Presented By
Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain
Conference
WCLC 2022
Trial
Phase 3, IMpower010
Doi
https://doi.org/10.55788/3bf61264
The first pre-specified interim overall survival (OS) analysis of the phase 3 IMpower010 trial displayed a trend towards an OS benefit for patients with stage II–IIIA, PD-L1-positive non-small cell lung cancer (NSCLC) if they were treated with adjuvant atezolizumab instead of best supportive care (BSC) [1]. The IMpower010 trial (NCT02486718) randomised 1,005 patients with completely resected, stage IB–IIIA NSCLC 1:1 to adjuvant atezolizumab or BSC. The primary analysis demonstrated a disease-free survival benefit of atezolizumab over BSC in the subset of participants with stage II–IIIA NSCLC and ≥1% PD-L1 tumour cells histologically (TC) (HR 0.66; 95% CI 0.50–0.88; P=0.004) [2]. These results led to the approval of adjuvant atezolizumab after resection and platinum-based chemotherapy in the USA, China, and Japan if patients had stage II–IIIA disease and ≥1% PD-L1 T...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on